Psychedelic R&D Biotechnology Biomind Labs Inc. BMNDFMore New Sublingual Formulation and First Production Batch to Test in Phase 2 Trials of BMND08, a Proprietary 5-MeO-DMT-Based Drug Candidate for the Treatment of Depressive and Anxiety Conditions in People with Alzheimer’s Disease Completed the development of impairment.
Biomind CEO Alejandro Antalich sees this step as a new milestone that strengthens the company’s “vertical integration” strategy and can potentially alleviate suffering for people with the condition.
“Over the last few decades, science has proven that life expectancy can be increased, but this realization may not be as good as we hoped. If not, does it make sense to live longer?The consequences of current lifestyles, routines, the long-term neurological effects of Covid-19, and lack of brain training are making neurodegenerative diseases common. We turned it into a disease,” said Antalich.
A major impetus for BioMind is to find solutions for these health conditions and potentially improve neuroplasticity in patients. We will do everything in our power to stop the invisible, slow and irreversible suffering that completely destroys the quality of life,” said the CEO.
A new sublingual route of administration enables, among other things, “convenient dosing for elderly and psychiatric uncooperative patients with dysphagia (dysphagia),” rapid absorption, predictable efficacy, and more. reduced drug and food interactions and relative ease of administration. to other delivery techniques.
Biomind’s CSO Dr. Paola Díaz Dellavalle said:
Tryptamines such as 5-MeO-DMT are taken orally because they are degraded by monoamine oxidase enzymes present in the gastrointestinal tract, preventing their absorption into the circulation and central nervous system. and neurochemically inactive, explained Díaz Dellavalle.
Therefore, monoamine oxidase inhibitors should be added to the oral route of administration to protect 5-MeO-DMT from first-pass metabolism. “This factor greatly increases formulation complexity and maximizes outcomes,” he concluded, his CSO at Biomind.
Photo courtesy of PopTika on Shutterstock and Harbin on Wikimedia Commons.
